BIIB
Biogen
$199.71
▲ 1.6%Updated Today 7:15 PM ET
▲ Up 55.4% over the last 12 months
Market Cap
$29.02B
P/E
21.13x
Forward P/E (est.)
22.98x
ROE
7.5%
Revenue Growth
1.2%
EPS Growth
-8.1%
Profit Margin
13.8%
FCF Yield
6.8%
Debt / Equity
0.34x
ROIC
11.0%
Interest Coverage
10.62x
Current Ratio
3.06x
Dividend Yield
—
Implied Growth (rev. DCF)
1.8%
Rating Score
49/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what BIIB's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. BIIB trades near $199.71, above its 50-day average ($190.15) and 200-day average ($174.41). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 53 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. BIIB's is $6.02 (~3.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month BIIB found buyers near $184.90 (support) and sellers near $203.45 (resistance); its 52-week range is $121.05–$205.97. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Biogen (BIIB) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $29.02B.
In its latest reported year it generated about $9.89B in revenue and $1.29B in net profit.
Our model rates BIIB Neutral (49/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
-2.6%
Revenue moved from $10.98B in 2021 to $9.89B in 2025, a -2.6% compound annual growth rate. The most recent year was roughly flat (1.2%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
75.5%
Operating Margin
17.5%
Net Margin
13.1%
ROE
7.5%
Biogen keeps about 13.8% of each sales dollar as net profit, with a 75.5% gross margin and 17.5% operating margin. Return on equity is 7.5% and return on invested capital about 11.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$6.29B
Net Debt
$3.37B
Net Debt / EBITDA
—
Debt / Equity
0.34x
Leverage: debt-to-equity is 0.3x, and operating profit covers interest about 10.6x, with a current ratio of 3.1x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $6.29B of total debt against $2.91B of cash.
Operating CF
$2.20B
Free Cash Flow
$2.05B
FCF Margin
20.7%
In the latest year Biogen produced about $2.20B of operating cash flow and $2.05B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.8% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
21.13x
P/S
2.92x
P/B
1.42x
EV / EBITDA
8.91x
BIIB trades at 21.1x trailing earnings (about 23.0x on estimated forward earnings), 2.9x sales, and 1.4x book value. Reverse-engineering today's price implies the market expects roughly 1.8% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How BIIB stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), BIIB ranks #36 of 59 by our overall rating. It trades at a discount versus the sector on earnings (21.1x P/E vs. 25.4x median) with a lower return on equity (7.5% vs. 14.9%) and slower revenue growth (1.2% vs. 7.9%).
P/E vs sector
21.1x
median 25.4x
ROE vs sector
7.5%
median 14.9%
Growth vs sector
1.2%
median 7.9%
Sector rank
#36
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$131.25 – $212.02
vs. $199.71 today · expected CAGR -8% – 1%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $10.19B | $10.49B | $10.81B | $11.13B | $11.47B |
| Net income | $1.32B | $1.36B | $1.41B | $1.45B | $1.49B |
| EPS | $8.97 | $9.24 | $9.52 | $9.80 | $10.10 |
| Share price (low) | $116.61 | $120.11 | $123.72 | $127.43 | $131.25 |
| Share price (high) | $188.38 | $194.03 | $199.85 | $205.84 | $212.02 |
| CAGR (low–high) | -42% / -6% | -22% / -1% | -15% / 0% | -11% / 1% | -8% / 1% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for BIIB:
- Healthy free-cash-flow yield (~6.8%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.3x) lowers risk.
The case against BIIB:
- Revenue growth is slow (1.2%), limiting the upside engine.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Growth risk — sluggish revenue (1.2%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Biogen is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 21.1x earnings, which our model scores Neutral (49/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.